Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined gemcitabine therapy on advanced pancreatic cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Changhai Hospital
• Collaborator: ImmunoGene Biotechology Co.,Ltd
• Treatments: Gemcitabine

Criteria

Inclusion Criteria:

1. Advanced Pancreatic cancer patients with histological pathology confirmation

2. Both gender, aged 18-70 year-old

3. Bone marrow functioned well

4. Renal function normal

5. Liver function normal

6. patients are voluntary, and willing to sign informed consent

7. expected lifetime was at least 3 months

Exclusion Criteria:

1. With acute inflammation

2. Accompanied with primary malignant tumor other than pancreas

3. with autoimmune disease

4. using corticosteroid or other suppress immune hormone treatment

5. had transplant operation of vital organs

6. active hepatitis

7. HIV positive

8. dysfunction in blood coagulation

9. serious diseases in circulatory and respiratory systems

10. pregnancy or breast-feeding women